Adverse Drug Reactions on the Skin
Özet
Physiological changes associated with aging are inevitable and complex processes that affect all living beings. The structural and functional changes observed during the aging process can lead to alterations in the distribution, metabolism, and excretion of medications in the body. Drug interactions are common in elderly patients due to polypharmacy resulting from comorbidities. The risks of adverse drug reactions, allergies, and adverse drug interactions increase in older patients because of polypharmacy. Additionally, age-related changes in physiological status, decreased mobility, increased disease burden, higher frequency of medication use, and a greater likelihood of forgetfulness and dementia further contribute to the incidence of adverse drug reactions. In elderly patients, unwanted drug reactions are often dose-related, non-immunological, and predictable in their effects. Due to comorbidities and polypharmacy, older adults are at significant risk for cutaneous drug reactions. Early recognition and treatment of cutaneous adverse drug reactions are crucial for preventing potentially permanent harm in the geriatric population, particularly in the presence of multiple diseases and geriatric syndromes.
Referanslar
Zazzara MB, Palmer K, Vetrano DL, Carfì A, Onder G. Adverse drug reactions in older adults: a narrative review of the literature. Eur Geriatr Med. 2021 Jun;12(3):463-473.
Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004 Feb;57(2):121-6.
Mannesse CK, Derkx FH, de Ridder MA, Man in ‘t Veld AJ, van derCammen TJ. Adverse drug reactions in elderly patients ascontributing factor for hospital admission: cross sectional study. Br Med J 1997; 315: 1057–8.
Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329:15-9.
Ray, W. A., Griffin, M. R., & Shorr, R. I. (1990). Adverse Drug Reactions and the Elderly. Health Affairs, 9(3), 114–122.
Bodur HA. İlaçlara bağlı olarak yaşlılarda sık karşılaşılan advers olaylar. Turkish Journal of Geriatrics Supplement, Özel Sayı, 2006 (49-52).
S ÜG. İlaç etkileşmeleri ve advers ilaç reaksiyonlarına yaklaşım. ETD. 2012;51.
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-9.
Williamson J, Chopim JM. Adverse reactions to prescribed drugs in the elderly. A multicentric investigation. Age Ageing 1980;9:73-7.
Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: A prospective study of 1756 patients. Drug Saf 2008;31(6):545-56.
Malhotra S, Karan RS, Pandhi P, Jain S. Drug related medical emergencies in the elderly: Role of adverse drug reactions and non-compliance. Postgrad Med J 2001;77:703-7.
Management Sciences for Health and World Health Organization (2007) Drug and Therapeutics Committee Training Course. Submitted to the U.S. Agency for International Development by the Rational Pharmaceutical Management Plus Program. Management Sciences for Health, Arlington.
Edwards IR, Aronson JK (2000) Adverse drug reactions: defnitions, diagnosis, and management. Lancet 356(9237):1255–1259.
Lattanzio F, Landi F, Bustacchini S et al (2012) Geriatric conditions and the risk of adverse drug reactions in older adults: a review. Drug Saf 35(Suppl 1):55–61.
Cullinan S, O’Mahony D, O’Sullivan D, Byrne S (2016) Use of a frailty index to identify potentially inappropriate prescribing and adverse drug reaction risks in older patients. Age Ageing 45(1):115–120.
Davies EA, O’Mahony MS (2015) Adverse drug reactions in special populations—the elderly. Br J Clin Pharmacol 80(4):796–807.
Koçyiğit SE. Geriatrik hastalarda ilaç alerjilerine genel yaklaşım. Bayrak Değirmenci P, editör. İlaç Alerjileri. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. p.96-102.
Tangiisuran B, Wright J, Van der Cammen T, Rajkumar C. Adverse drug reactions in elderly: challenges in identification and improving preventative strategies, Age and Ageing, Volume 38, Issue 4, July 2009, Pages 358–359.
Brahma DK, Wahlang JB, Marak MD, Sangma MCh. Adverse drug reactions in the elderly. Journal of Pharmacology and Pharmacotherapeutics. 2013;4(2):91-94.
Young JWS, Shear NH. Cutaneous Drug Reactions in the Elderly. Drugs Aging. 2017 Sep;34(9):655-672.
Heng, Y. K., & Lim, Y. L. (2015). Cutaneous adverse drug reactions in the elderly. Current Opinion in Allergy and Clinical Immunology, 15(4), 300–307.
Sullivan JR, Shear NH. Drug eruptions and other adverse drug effects in aged skin. Clin Geriatr Med. 2002 Feb;18(1):21-42.
Epstein JH. Phototoxicity and photoallergy. Semin Cutan Med Surg. 1999;18:274–84.
Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol. 2002;14:212–6.
Ma L, Danoff TM, Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133:1075–83.
Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol. 2011;29:455–7.
Korman NJ, Eyre RW, Zone J, Stanley JR. Drug-induced pemphigus: autoantibodies directed against the pemphigus antigen complexes are present in penicillamine and captopril induced pemphigus. J Invest Dermatol. 1991;96:273–6.
Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol. 2014;28:1133–40.
Bastuji-Garin S, Joly P, Picard-Dahan C, et al. Drugs associated with bullous pemphigoid: a case-control study. Arch Dermatol. 1996;132:272–6.
Fortuna G, Salas-Alanis JC, Guidetti E, Marinkovich MP. A critical reappraisal of the current data on drug-induced linear immunoglobulin A bullous dermatosis: a real and separate nosological entity? J Am Acad Dermatol. 2012;66:988–94.
Chantaphakul H, Sanon T, Klaewsongkram J. Clinical characteristics and treatment outcome of Stevens–Johnson syndrome and toxic epidermal necrolysis. Exp Ther Med. 2015;10(2): 519–24.
Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens–Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with metaregression of observational studies. Int J Dermatol. 2015;54: 108–15.
Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014;71:278–83. doi:10.1016/j.jaad.2014.04.044.
Chang S-L, Huang Y-H, Yang C-H, et al. Clinical manifestations and characteristics of patients with acute generalized exanthematous pustulosis in Asia. Acta Derm Venereol. 2008;88:363–5.
Nazarian RM, Van Cott EM, Zembowicz A, Duncan LM. Warfarin-induced skin necrosis. J Am Acad Dermatol. 2009;61:325–32.
White PW, Sadd JR, Nensel RE. Thrombotic complications of heparin therapy: including six cases of heparin-induced skin necrosis. Ann Surg. 1979;190:595–608.
Radic´ M, Martinovic´ Kaliterna D, Radic´ J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med. 2012;70:12–7.
Lowe GC, Lowe G, Henderson CL, et al. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011;164:465–72.
